CN209596610U - A kind of blood plasma methylenum careuleum virus inactivating filter device - Google Patents
A kind of blood plasma methylenum careuleum virus inactivating filter device Download PDFInfo
- Publication number
- CN209596610U CN209596610U CN201920238208.5U CN201920238208U CN209596610U CN 209596610 U CN209596610 U CN 209596610U CN 201920238208 U CN201920238208 U CN 201920238208U CN 209596610 U CN209596610 U CN 209596610U
- Authority
- CN
- China
- Prior art keywords
- methylenum careuleum
- blood plasma
- woven fabrics
- lumen
- aperture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 79
- 241000700605 Viruses Species 0.000 title claims abstract description 32
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 19
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 65
- 229920000049 Carbon (fiber) Polymers 0.000 claims abstract description 26
- 239000004917 carbon fiber Substances 0.000 claims abstract description 26
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000001179 sorption measurement Methods 0.000 claims abstract description 23
- 230000008676 import Effects 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 7
- 238000001914 filtration Methods 0.000 abstract description 62
- 239000000463 material Substances 0.000 abstract description 26
- 230000001376 precipitating effect Effects 0.000 abstract description 5
- 238000001556 precipitation Methods 0.000 abstract description 3
- 238000010828 elution Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 40
- 230000000694 effects Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241000701370 Plasmavirus Species 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000000016 photochemical curing Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model discloses a kind of blood plasma methylenum careuleum virus inactivating filter devices, including import lumen, the multistage intermediary canal for exporting lumen and having certain space volume, the junction of two neighboring lumen is provided with filter layer, coarse filter area, methylenum careuleum adsorption zone and leucocyte-removing area successively are formed in lumen junction from import to outlet.The utility model separates filtering material non-woven fabrics and carbon fiber to form independent multiple filtering function regions with cavity, the tower multi-filtering of elution can be achieved, so as to effectively improve the utilization efficiency of filtering material, promote the removal rate of methylenum careuleum, reduce the loss of blood plasma, and strainability is stablized, being effectively reduced albumen precipitation and floccule precipitating bring in blood plasma influences.
Description
Technical field
The utility model relates to a kind of medical devices more particularly to a kind of blood plasma methylenum careuleum virus inactivating filter devices.
Background technique
Blood-plasma virus killing composition product is the substitute products of blood plasma product, and the purpose is to prevent high risk after plasma infusion
Viral infection.Common methylenum careuleum virus inactivated plasma method in world wide at present, can effectively inactivate lipid envelope in blood plasma
Virus and part non-lipid enveloped virus, such as: the harm that HBV, HCV, HIV health administration department must detect and control
The big virus of property.The effect of methylenum careuleum virus inactivated plasma filter device is, after removal methylenum careuleum photochemical treatment in blood plasma
The methylenum careuleum of remaining, the methylenum careuleum content in methylenum careuleum virus inactivated plasma is reduced as far as possible, thus when large dosage is transfused
Methylenum careuleum exposure minimize；The leucocyte in blood plasma is removed, simultaneously to reduce the generation of the transfusion reactions such as FNHTR.
Filter currently used in the market be it is flat discoid or rectangular, filter material (including non-woven fabrics and carbon fiber) with
Close pressing mode is fixed in filter shell, then keeps filter shell closed in a manner of welding or heat seal.Filter type is side
Face osmosis, i.e. import and outlet are parallel with filtering surface.In practical applications, in order to guarantee effective methylenum careuleum and leucocyte
Removal effect, flat filtering surface is both needed to using biggish diameter, and generally between 40mm~70mm, foreign countries are directed to
The methylenum careuleum virus inactivated plasma of 300ml or more even uses the diameter of 100mm；Cost is not only increased, and is greatly increased
The loss amount of blood plasma.Further, since filter table area is big, it is to be filtered when blood plasma is entered in filtering material from the inlet face of filtering
Liquid usually passes through from easy filtration position, tends not to all and is arrived by infiltration, filtering material to filtering material at the end of filtering
Effective rate of utilization it is low.On the other hand, due to non-woven fabrics and carbon fibre material in filter it is tightly stacked together, centre does not have
Cushion space exists, and is easy in actual use because blocking the problems such as a small amount of fibrin deposition in blood plasma, thus
Affect the effect of filtering, in addition it is serious when lead to not complete filter process.
Utility model content
Technical problem to be solved in the utility model is for plasma volume range in 100ml~500ml, especially right
200ml is provided a kind of blood plasma methylenum careuleum virus inactivating filter device, can be effectively improved filtering material with the plasma volume of upper volume
Utilization rate, promote the removal rate of methylenum careuleum, reduce the loss of blood plasma, and strainability is stablized, and egg in blood plasma is effectively reduced
White precipitation and floccule precipitating bring influence.
The utility model is to solve above-mentioned technical problem and the technical solution adopted is that provide a kind of blood plasma methylenum careuleum virus
Filter device is inactivated, including import lumen, outlet lumen and multistage intermediary canal, the junction of two neighboring lumen are provided with
Filter layer successively forms coarse filter area, methylenum careuleum adsorption zone and leucocyte-removing area in lumen junction from import to outlet.
Further, the coarse filter area is made of the biggish non-woven fabrics in multilayer aperture, and non-woven fabrics aperture is in 70 μm~100 μ
M, the number of plies is between 1~4；The leucocyte removal area is made of the thinner non-woven fabrics in multilayer aperture, aperture at 12 μm~21 μm,
The number of plies is between 2~4.
Further, the number of plies of the non-woven fabrics in the leucocyte removal area is 4 floor, 12 μm~21 μm of aperture, from import
To export direction, from 21 μm, 18 μm, 15 μm to 12 μm successively gradient declines.
Further, intermediary canal and filter layer, the mistake are also set up between the leucocyte removal area and outlet lumen
Filtering layer is shaped to microorganism removal area by the non-woven fabrics group in 0.65 μm~0.22 μm of 10~14 floor aperture.
Further, the methylenum careuleum adsorption zone is composed of carbon fiber and non-woven fabrics, and the carbon fiber overall thickness is 4
Between~12mm, the non-woven fabrics aperture is between 21~35 μm, and the number of plies is between 1~2；The non-woven fabrics folder is in the carbon fibers
Between or be spaced apart.
Further, the number of plies of non-woven fabrics is two layers in the methylenum careuleum adsorption zone, and layer of non-woven fabric aperture is arrived along tube wall
Lumen center is gradient to 35 μm by 21 μm, and another layer of non-woven fabric aperture is gradient to 21 μm by 35 μm along tube wall to lumen center.
Further, the spatial volume of the multistage intermediary canal is controlled at 100 cubic millimeters~3000 cubic millimeters.
Further, the intermediary canal inner wall is equipped with along the forward diversion trench of plasma flow direction spiral；The methylene
The spiral opposite direction of diversion trench on blue adsorption zone two sides intermediary canal inner wall.
The utility model comparison prior art has following the utility model has the advantages that blood plasma methylenum careuleum virus provided by the utility model
Inactivate filter device, be different from it is existing by filtering material non-woven fabrics it is tightly stacked with carbon fiber together with the filter type that permeates,
It separates filtering material non-woven fabrics and carbon fiber to form independent multiple filtering function regions, each filter element has slow
Space is rushed to store waste, realizes and elutes tower multi-filtering, so as to effectively improve the removal rate of methylenum careuleum, is reduced
The loss of blood plasma, and strainability is stablized, and filter effect is effectively improved, and reduces plasma protein precipitation and floccule sealed Belt comes
Blocking influence.
Detailed description of the invention
Fig. 1 is the utility model blood plasma methylenum careuleum virus inactivating filter apparatus structure schematic diagram.
Specific embodiment
The utility model will be further described with reference to the accompanying drawings and examples.
Fig. 1 is utility model blood plasma methylenum careuleum virus inactivating filter apparatus structure schematic diagram.
Referring to Figure 1, blood plasma methylenum careuleum virus inactivating filter device provided by the utility model, including import lumen 1, go out
Mouth lumen 3 and multistage intermediary canal 2, the junction of two neighboring lumen are provided with filter layer, successively exist from import to outlet
Lumen junction forms coarse filter area 4, methylenum careuleum adsorption zone 5 and leucocyte-removing area 6.The utility model by filtering material non-woven fabrics and
Carbon fiber separates and is formed independent filtering function region, is divided into coarse filter area 4, methylenum careuleum adsorption zone 5, leucocyte-removing area 6；Each area
Domain is connected with multistage intermediary canal 2, and each intraluminal junction is tightly fixed in a manner of gluing etc.；It can be achieved to be in eluting column
The multi-filtering of formula.
The blood plasma methylenum careuleum virus inactivating filter device of the utility model, the coarse filter area 4 is by the biggish nothing in multilayer aperture
Woven fabric composition, non-woven fabrics aperture is at 70 μm or more, and preferably 70 μm~100 μm, the number of plies tentatively filters out fine in blood plasma between 1~4
Fibrillarin is precipitated and floccule precipitating, plays the role of anti-clogging.Existing filter type is compared in the presence of coarse filtration layer, is resisted stifled
Plug ability is obviously improved, and is mainly reflected in that the rate of filtration is fast and relatively stable, and filtration time deviation is smaller, and shortens
The time is filtered, the working time for shortening operator is facilitated
The blood plasma methylenum careuleum virus inactivating filter device of the utility model, the methylenum careuleum adsorption zone 5 is by carbon fiber and nothing
Woven fabric is composed, wherein carbon fiber overall thickness is between 4~12mm, and non-woven fabrics aperture is between 21~35 μm, and the number of plies is 1
Between~2；Carbon fiber adsorption methylenum careuleum, and non-woven fabrics is clipped among carbon fiber or is spaced apart, and plays certain flow velocity and adjusts
Effect, to reinforce the adsorption effect of methylenum careuleum.
Preferably, the number of plies of non-woven fabrics is two layers in methylenum careuleum adsorption zone 5, and layer of non-woven fabric aperture is along tube wall into lumen
Centre is gradient to 35 μm by 21 μm, and another layer of non-woven fabric aperture is gradient to 21 μm by 35 μm along tube wall to lumen center；Pass through part
The variation of radial flow speed so that carbon fiber preferably carries out absorption cladding to methylenum careuleum virus, and does not influence integral filter speed；
Part blood plasma forms certain detour and washes away simultaneously, and effectively prevent protein to be precipitated causes methylenum careuleum to be inhaled with the deposition of floccule etc.
Attached area 5 blocks.
The blood plasma methylenum careuleum virus inactivating filter device of the utility model, the leucocyte-removing area 6 are thinner by multilayer aperture
Non-woven fabrics composition, aperture is within 21 μm, and preferably 12 μm~21 μm, the number of plies is surplus in blood plasma to filter out between 2~4
Remaining leucocyte.In addition, as needed can also leucocyte removal area 6 select the ultra-fine aperture of multilayer non-woven fabrics, reinforced be
Microorganism and leucocyte removal area, generally by 1~2 layer 0.22 μm of aperture < of non-woven fabrics and 10~12 layers 0.65 μm of aperture <
Non-woven fabrics, it is therefore an objective to intercept the bacterium in blood plasma, achieve the effect that remove microbial contamination in blood plasma.Certainly, by increasing by one
Section intermediary canal 2 additionally increases microorganism removal area's (not shown) in 6 lower end of leucocyte removal area.
Preferably, the number of plies of the non-woven fabrics in leucocyte removal area 6 is 4 floor, aperture direction from inlet to outlet, from 21 μ
M, 18 μm, 15 μm to 12 μm successively gradient declines, to take into account filter material dosage, the rate of filtration and Blood index loss amount.
Different from existing flat structure and the filtering material filter type stacked together infiltrated from side, use is tower
It takes a shower after integral structure, filtering surface diameter is significantly reduced, and filtering material non-woven fabrics and carbon fiber are separated, and is formed independent
Filtering function region, the lumen of centre setting certain space volume, what is obtained compared with original device has the beneficial effect that
1) removal rate of methylenum careuleum is effectively improved, removal rate improves about 16%；
2) loss amount of blood plasma is reduced, loss amount reduces about 39.6%；
3) material effective rate of utilization is 4 times of existing apparatus, and strainability is stablized.
4) filtration time about 20.1% can be shortened, shorten the working time of operator.
5) plasmapheresis anti-blockage capability is promoted, and can be effectively reduced albumen precipitation and floccule precipitating bring in blood plasma
It influences.
6) it can effectively avoid existing apparatus from there is a situation where side leakage short circuit, ensure that the stabilization of strainability.
7) the utility model can also increase a microorganism removal area, and blood plasma is removed in the case where not reducing strainability
In microorganism.
In the embodiments of the present invention, because the lumen of setting is the cavity for having certain spatial volume, so that flow direction
Filtering layer surface can be completely covered in the liquid of filter layer, avoid only passing through from passage portion because of fluid inertia, guarantee sufficiently benefit
Use filtering material；Even if gas can also pass through the entire lumen for making from import to outlet simultaneously during the filtration process, keep away
Exempt to generate negative pressure because of cavitation erosion, when being combined with multi-joint plasma bags, the setting of By-pass vent pipeline can be saved in design.Work as inlet tube
When chamber 1, intermediary canal 2 and outlet lumen 3 are that hard PVC is molded, interior lumen construction is as shown in Figure 1；But this
Lumen material used in embodiment is not limited to hard PVC, other suitable materials, such as PP, PC can also be used；Meanwhile
Soft medical plastic also can be used and be fabricated to soft filter device, to adapt to whole centrifugation.When use medical polypropylene material, gather
When carbonic ester or other hard materials are molded, bonded using UV glue or other suitable binders, while carrying out photocuring
5~10s is handled to enhance the firmness of bonding.
Integral molded plastic or Split injection manufacture filter device surgery can be used in the present embodiment；Filter device fission is molded respectively
When, outside uses step structure in each 2 edge of lumen, so that filter layer is tightly fixed to each lumen junction by adhesive means
Step on.Specific preparation process is as follows:
S1, first injection molding form import lumen 1, outlet lumen 3 and multistage intermediary canal 2, and in the intermediary canal 2 one
Step structure is formed on the outside of end margin, while step structure is formed on the inside of another end margin, the lower end edge of the import lumen 1
It is formed with step structure on the inside or outside of edge, is formed with step structure on the inside or outside of the upper end-face edge of the outlet lumen 3.
S2, then will non-woven fabrics and carbon fiber superposition compress after cutting form filter layer, then by tetrahydrofuran and hexamethylene
Ketone is used as binder by 2:1 mixing, filter layer is tightly fixed on the step of each lumen junction；
S3, finally each lumen linked together by above-mentioned binder, blood plasma approach import lumen 1, coarse filter area 4, in
Between lumen 2, methylenum careuleum adsorption zone 5, intermediary canal 2, leucocyte-removing area 6 to outlet lumen 3, formed and elute tower multiple mistake
Filter.
The spatial volume of the multistage intermediary canal of the present embodiment is 100 cubic millimeters~3000 cubic millimeters, every section of centre
The diameter of lumen 2 is 20mm~25mm, and 1 arrival end of import lumen and the diameter for exporting 3 outlet end of lumen are less than intermediate tube
The diameter of chamber 2, the import lumen 1 and the diameter for exporting 3 other end of lumen are consistent with the diameter of intermediary canal 2；Subtract significantly
The volume of small whole device, the total length after each lumen connection is no more than 6cm, preferably 4cm~6cm；To being convenient to and
Existing acquisition device of donating blood is connected.
In addition, 2 inner wall of intermediary canal of the present embodiment can be also equipped with along the forward diversion trench of plasma flow direction spiral (figure
Do not show)；The plasmapheresis flow velocity for being generally proximal to lumen wall is slower than the flow velocity of lumen center, and features described above makes intermediary canal
Inner wall is consistent with the mean flow rate in center, and can form certain turbulent flow, is better protected from clogging.The methylene
The spiral opposite direction of diversion trench on blue 5 two sides intermediary canal of adsorption zone, 2 inner wall, to play certain gather to flocky precipitate
Hold together effect, preferably to adsorb to methylenum careuleum virus.For the lumen using step structure, diversion trench extends through platform
Rank to not only can guarantee that filter layer and lumen were tightly fastened, but also can preferably avoid influencing filter effect.
In the present embodiment, coarse filter area 4 is made of the non-woven fabrics in 1~4 layer of 70 μm of aperture or more, be fixed on import lumen 1 with
Between intermediary canal 2；Methylenum careuleum adsorption zone 5 by the carbon fiber of 4~12mm of overall thickness and 1~2 layer of 21~35 μm of aperture nonwoven
Cloth composition, non-woven fabrics are clipped between carbon fiber or are spaced apart, be fixed between two sections of intermediary canals 2；Leucocyte-removing area 6 is by 2
Non-woven fabrics composition of~4 layers of aperture less than 21 μm, is fixed between outlet lumen 3 and intermediary canal 2, while can be selected 1~2 layer
The non-woven fabrics and 10~12 layers 0.65 μm of aperture < of non-woven fabrics that 0.22 μm of aperture < are reinforced going for microorganism and leucocyte
Except area's (not shown).
Blood plasma can be paved with 4 surface of coarse filter area after entering by import lumen 1, make full use of filter material；Through 4 mistake of coarse filter area
Filter, removal blood plasma inner fibrin is precipitated and the influence of floccule precipitating；5 table of methylenum careuleum adsorption zone is paved with by intermediary canal 2
Face removes methylenum careuleum through filtering；It is paved with 6 surface of leucocyte-removing area through intermediary canal 2 again, through filtering removing leukocytes.
The utility model is using minimum filter area in commercially available existing 200ml methylenum careuleum virus inactivated plasma filtering consumptive material
The mix proportion scheme and 200ml of φ 40mm filter, as filtering solution, carry out equivalent filtering containing the blood plasma of about 3 μm of ol/L methylenum careuleum
Comparative experiments to verify the actual utility of the utility model.The utility model made diameter phi be respectively 15mm, 20mm and
Three embodiments of 25mm, to look for most suitably used filter sizes.
It is under equal conditions verified, from filtration time, the filtration time of diameter phi 15mm group compares existing apparatus
(diameter 40mm) extends 8.5%, and the filtration time of diameter phi 20mm group shortens about 19% than existing apparatus, diameter phi 25mm group
Filtration time than existing apparatus shorten about 31.8%；From the point of view of methylenum careuleum residual quantity, the methylenum careuleum of diameter phi 15mm group is remained
Than existing apparatus increase about 122.6%, the methylenum careuleum residual of diameter phi 20mm group reduces about 18.3% than existing apparatus, diameter phi
The methylenum careuleum residual of 25mm group reduces about 25.5% than existing apparatus；From the point of view of blood plasma loss amount, the blood plasma of diameter phi 15mm group
Damage loss amount than existing apparatus reduce about 47.9%, the blood plasma loss amount of diameter phi 20mm group fewer than existing apparatus about 37.2%,
The blood plasma loss amount of φ 25mm group fewer than existing apparatus about 14.9%.Due to when blood plasma loses less, methylenum careuleum residual is low and filtering
Between it is short be that virus inactivated plasma filters be primarily upon index, and from pair of above-mentioned three kinds of design schemes and existing matured product
From the point of view of test result, the utility model assert the embodiment of φ 20mm in blood plasma loss amount, methylenum careuleum residual and filtration time
On be superior to existing apparatus, be significantly improved.And the cases of design of diameter phi 15mm is in filtration time and methylenum careuleum residual quantity
On be inferior to existing apparatus, the cases of design of diameter phi 25mm is although remain upper optimal, blood plasma in filtration time and methylenum careuleum
Waste will increase about 22% compared with diameter phi 20mm.Therefore, amid all these factors, the design scheme of diameter phi 20mm is determined
To optimize example.The material embodiments of diameter phi 20mm are further verified, still using with existing maturing appts into
Row compares.Test result verifying shows that compared with the prior device filtration time reduces 12.90% -27.30%, and methylenum careuleum is residual
Reduction 12.90% -19.35% is stayed, blood plasma waste reduces 32.82% -46.37%, explanation consistent with data before this
The embodiment of diameter phi 20mm is feasible.
The utility model has tested influence of the different ratio to strainability with the embodiment of diameter phi 20mm, and according to reality
It tests result and optimal proportion has been determined, is i.e. coarse filter area 4 is made of the non-woven fabrics in 1~4 layer of 70 μm of aperture or more, methylenum careuleum adsorption zone 5
It is made of the non-woven fabrics of the carbon fiber of 4~12mm of overall thickness and 1~2 layer of 21~35 μm of aperture, leucocyte-removing area 6 is by 2~4 floor hole
Non-woven fabrics composition of the diameter less than 21 μm.The non-woven fabrics in 70 μm of the aperture that coarse filter area 4 is selected or more, can effectively intercept in blood plasma
Fibrin deposition, and the rate of filtration is influenced smaller, but when reaching 5 layers, the stability of the rate of filtration declines, and partially goes out
The now slow situation of liquid.The utility model collects the blood plasma for having obvious fibrin deposition, and mixing is divided equally, to verify different holes
The anti-blockage capability of the single-layer nonwoven of diameter.Experimental result shows that 21 μm of non-woven fabrics apparent blocking occurs and pressurizeing
Under the conditions of can not still pass through；Also there is clogging in 35 μm and 45 μm of non-woven fabrics, but blood plasma can lead under an increased pressure
It crosses；And 70 μm of non-woven fabrics does not cause blockages then.It selects 70 μm of the non-woven fabrics of 200ml using blood plasma as liquid, verifies nothing
Influence of the woven fabric number of plies to flow velocity.Experimental result shows that the flow velocity time-consuming of one to five layers of non-woven fabrics is significantly increased at five layers, out
Show the case where liquid outflow takes a long time, and difference is unobvious in the case of one to four layers.Therefore, coarse filter area selects 1~4 layer 70
μm or more non-woven fabrics when can get preferable effect.
Non-woven fabrics in methylenum careuleum adsorption zone 5 plays the buffer function of coutroi velocity, absorption caused by avoiding flow velocity too fast
It is ineffective, but the number of plies excessively then can significantly influence the rate of filtration, select 3 layers or more of the non-woven fabrics rate of filtration that can reduce
25% or so.And the thickness of carbon fiber, in 4mm, the residual quantity of methylenum careuleum has met the requirement of concerned countries standard, is reaching
When 12mm, methylenum careuleum is almost examined and is not measured.Therefore it selects by the carbon fiber of 4~12mm of overall thickness and 1~2 layer of 21~35 μm of aperture
Non-woven fabrics is preferably.
Carbon fiber is clogged in intermediary canal 2 can further promote methylenum careuleum adsorption effect, such as reality in above-mentioned φ 20mm
It applies and adds in example into one layer of carbon fiber, methylenum careuleum residual reduces 30% or so.
The non-woven fabrics selection in leucocyte-removing area 6 is then according to the experimental data accumulation of many years, the nonwoven in two layers of 21 μm of apertures
Cloth is able to satisfy the blood plasma leucocyte-removing requirement that two unit whole bloods separate, according to 2015 editions blood transfusion regulations for technical operation the methods
The white blood cell count(WBC) experimental result of progress does not find that leucocyte remains；And with the increase of the non-woven fabrics number of plies, filtering rate drop
It is low that amplitude is increasing.Comprehensively consider, selects 2~4 layers of non-woven fabrics of aperture less than 21 μm.
The utility model, which also demonstrates the present apparatus, can reach the minimalist configuration scheme of existing professional standard, i.e., coarse filter area 4 by
One layer 70 μm of non-woven fabrics composition, methylenum careuleum adsorption zone 5 are pressed from both sides one layer 21 μm of non-woven fabrics group by the carbon fiber of two layers of overall thickness 4mm
It is made of at, leucocyte-removing area 6 two layers of 17 μm of non-woven fabrics.Experiment uses the blood plasma of about 220ml, adds illumination after methylenum careuleum
About 1 μm of ol/L of preceding methylenum careuleum concentration carries out filtration test after normal illumination inactivates process, the experimental results showed that properties are equal
Meet relevant national standard requirement.
The utility model embodiment also analyzes the variation of filtering Plasma Before And After ingredient, experimental result display filtering
The rate of recovery of major protein (total protein, albumin, globulin, PROTEIN C etc.) is effective in 85% or more, blood plasma in Plasma Before And After
The rate of recovery of coagulation factor activity (such as FVIII, fibrinogen, antithrombase) is 80% or more, with existing apparatus to blood
The influence of liquid ingredient is consistent, does not increase on the influence of the quality of plasma composition.
In conclusion the utility model embodiment is minimum on the main active influence in blood plasma, properties are accorded with
Relevant criterion requirement is closed, and compared with existing filter device, had a clear superiority in the rate of filtration, filtering waste, simultaneously
The application efficiency for substantially increasing filtering material, on the basis of saving 75% filtering material, the rate of filtration improves 20.1%,
Methylenum careuleum absorption property improves 16.1%, and blood plasma waste reduces 39.6%, and entirety bonds the mode assembled also more
Existing filter device welding manner is mended to the defect of filtering material hypopexy.
Although the utility model is disclosed as above with preferred embodiment, so it is not intended to limit the utility model, any
Those skilled in the art, without departing from the spirit and scope of the utility model, when can make a little modification and it is perfect, therefore this
The protection scope of utility model, which is worked as, to be subjected to the definition of the claims.
Claims (8)
1. a kind of blood plasma methylenum careuleum virus inactivating filter device, which is characterized in that including import lumen (1), outlet lumen (3) with
And multistage intermediary canal (2), the junction of two neighboring lumen are provided with filter layer, successively connect in lumen from import to outlet
Place is formed coarse filter area (4), methylenum careuleum adsorption zone (5) and leucocyte-removing area (6).
2. blood plasma methylenum careuleum virus inactivating filter device as described in claim 1, which is characterized in that the coarse filter area (4) by
The biggish non-woven fabrics composition in multilayer aperture, non-woven fabrics aperture is at 70 μm~100 μm, and the number of plies is between 1~4；The leucocyte is gone
Except area (6) are made of the thinner non-woven fabrics in multilayer aperture, aperture is at 12 μm~21 μm, and the number of plies is between 2~4.
3. blood plasma methylenum careuleum virus inactivating filter device as claimed in claim 2, which is characterized in that the leucocyte removal area
(6) number of plies of the non-woven fabrics in is 4 layers, 12 μm~21 μm of aperture；Direction from inlet to outlet, from 21 μm, 18 μm, 15 μm to 12
μm successively gradient declines.
4. blood plasma methylenum careuleum virus inactivating filter device as claimed in claim 2, which is characterized in that the leucocyte removal area
(6) outlet lumen (3) between also settable intermediary canal and filter layer, the filter layer by 11~14 layers of 0.65 μm of aperture~
0.22 μm of non-woven fabrics group is shaped to microorganism removal area.
5. blood plasma methylenum careuleum virus inactivating filter device as described in claim 1, which is characterized in that the methylenum careuleum adsorption zone
(5) it is composed of carbon fiber and non-woven fabrics, the carbon fiber overall thickness is between 4~12mm, and the non-woven fabrics aperture is 21
Between~35 μm, the number of plies is between 1~2；The non-woven fabrics is clipped among carbon fiber or is spaced apart.
6. blood plasma methylenum careuleum virus inactivating filter device as claimed in claim 5, which is characterized in that the methylenum careuleum adsorption zone
(5) number of plies of non-woven fabrics is two layers in, and layer of non-woven fabric aperture is gradient to 35 μm by 21 μm along tube wall to lumen center, another layer
Non-woven fabrics aperture is gradient to 21 μm by 35 μm along tube wall to lumen center.
7. blood plasma methylenum careuleum virus inactivating filter device as described in claim 1, which is characterized in that the multistage intermediary canal
Spatial volume be 100 cubic millimeters~3000 cubic millimeters.
8. blood plasma methylenum careuleum virus inactivating filter device as described in claim 1, which is characterized in that the intermediary canal (2)
Inner wall is equipped with along the forward diversion trench of plasma flow direction spiral；Methylenum careuleum adsorption zone (5) two sides intermediary canal (2) inner wall
On diversion trench spiral opposite direction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201920238208.5U CN209596610U (en) | 2019-02-25 | 2019-02-25 | A kind of blood plasma methylenum careuleum virus inactivating filter device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201920238208.5U CN209596610U (en) | 2019-02-25 | 2019-02-25 | A kind of blood plasma methylenum careuleum virus inactivating filter device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209596610U true CN209596610U (en) | 2019-11-08 |
Family
ID=68403012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201920238208.5U Withdrawn - After Issue CN209596610U (en) | 2019-02-25 | 2019-02-25 | A kind of blood plasma methylenum careuleum virus inactivating filter device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN209596610U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109663385A (en) * | 2019-02-25 | 2019-04-23 | 上海输血技术有限公司 | A kind of blood plasma methylenum careuleum virus inactivating filter device and preparation method thereof |
-
2019
- 2019-02-25 CN CN201920238208.5U patent/CN209596610U/en not_active Withdrawn - After Issue
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109663385A (en) * | 2019-02-25 | 2019-04-23 | 上海输血技术有限公司 | A kind of blood plasma methylenum careuleum virus inactivating filter device and preparation method thereof |
| CN109663385B (en) * | 2019-02-25 | 2024-03-12 | 上海输血技术有限公司 | Plasma methylene blue virus inactivation and filtration device and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1582228B2 (en) | Method of removing leukocytes, leukocyte-removing filter and utilization thereof | |
| JP3388352B2 (en) | Bone marrow kit | |
| US8496833B2 (en) | Leukocyte removal method | |
| US8900462B2 (en) | Method for removing leukocyte and filter for use therein | |
| CN103313738B (en) | blood processing filter | |
| JP5806815B2 (en) | Blood treatment filter and blood filtration method | |
| JPH0614969B2 (en) | Liquid filtration device | |
| CA2405443A1 (en) | Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species | |
| US8763816B2 (en) | Filter for processing blood | |
| JPWO2012039402A1 (en) | Blood processing filter and method for manufacturing blood processing filter | |
| JP5631731B2 (en) | Blood treatment filter | |
| CN209596610U (en) | A kind of blood plasma methylenum careuleum virus inactivating filter device | |
| CN109663385A (en) | A kind of blood plasma methylenum careuleum virus inactivating filter device and preparation method thereof | |
| JP4965212B2 (en) | Blood treatment filter | |
| JP2011255043A (en) | Blood processing filter | |
| JP2559615B2 (en) | Leukocyte capture filter for concentrated red blood cells | |
| JPH0614968B2 (en) | Leukocyte capture and separation device | |
| JP4144707B2 (en) | Blood treatment filter | |
| JP2005237791A (en) | Method and system for filtering blood | |
| JP3419831B2 (en) | Aggregate removal filter in blood and filter device for blood treatment | |
| JP5710244B2 (en) | Blood processing filter | |
| JP5783852B2 (en) | Blood treatment filter | |
| Lundberg et al. | A biochemical study of the influence upon blood cells by four different leukocyte-removal filters | |
| JPH01207240A (en) | Blood washing device | |
| JP2011235188A (en) | Blood treatment filter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20191108 Effective date of abandoning: 20240312 |
|
| AV01 | Patent right actively abandoned |
Granted publication date: 20191108 Effective date of abandoning: 20240312 |
|
| AV01 | Patent right actively abandoned | ||
| AV01 | Patent right actively abandoned |